Home
Vertex Pharmaceuticals to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the ASA Annual Meeting.

Vertex Pharmaceuticals to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the ASA Annual Meeting.

Today’s Highlights October 18, 2024

Vertex Pharmaceuticals Announcement

October 18, 2024, Vertex Pharmaceuticals  (VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
October 18, 2024

Other Articles